Updated on October 29, 2026 · Reading time: 10 minutes
Short answer: Substances such as psilocybin and MDMA are being studied worldwide as part of psychotherapy. They have not yet been approved as treatments in the Netherlands. Esketamine, however, has been approved as a nasal spray for treatment-resistant depression. In Australia, specially certified psychiatrists have been authorized to prescribe psilocybin and MDMA since 2023. Research is promising but not yet complete.
Twenty years ago, it was a fringe phenomenon. Now, leading journals such as *The New England Journal of Medicine* and *JAMA* are publishing articles on psychedelic therapy. Universities are opening research centers, and governments are considering new regulations. What exactly is going on?
In this article, you’ll learn how psychedelic therapy works and which substances are being studied. We’ll summarize the most important studies and findings. You’ll also learn about the current situation in the Netherlands and why experimenting on your own is not the same as therapy.
Table of Contents
What is psychedelic therapy?
In psychedelic therapy, a patient is administered a psychedelic substance under supervision. This takes place in a quiet treatment room, often with an eye mask and music. Two therapists remain present throughout the session. The substance is not used in isolation; the session is part of a treatment program that includes counseling sessions before and after.
Researchers also refer to this as psychedelic-assisted psychotherapy. The idea is that the substance opens up a period during which people can view their thoughts and memories differently. The conversations help them make sense of that experience. This is called integration.
A Brief History
In the 1950s and 1960s, a great deal of research was already being conducted on LSD and psilocybin. Hundreds of studies were published, including research on alcohol addiction. LSD was also used in the Netherlands, for example by psychiatrist Jan Bastiaans to treat people suffering from war trauma. After the international ban in 1971, research virtually came to a halt.
Around 2000, research resumed. In 2006, Johns Hopkins University published a well-known study on psilocybin and mystical experiences. This was followed by studies at Imperial College London, NYU, and other universities. Hundreds of studies are now underway worldwide.
Which drugs are being studied?
Psilocybin
Psilocybin is the active ingredient in magic mushrooms and magic truffles. It is primarily being studied for depression that does not respond to conventional treatments. In 2025, the British company Compass Pathways reported positive results from its first large Phase 3 trial. In addition, studies are underway on addiction, anxiety associated with serious illness, and eating disorders. It has not yet been approved as a medication in Europe.
MDMA
MDMA has been studied as an adjunct to therapy for post-traumatic stress disorder, or PTSD for short. The American company Lykos Therapeutics submitted an application for approval to the FDA. In August 2024, the FDA rejected the application and requested an additional study. There were concerns regarding the study design and safety.
Ketamine and esketamine
Ketamine is an anesthetic that is being studied in low doses for the treatment of depression. Esketamine is a variant that has been approved in the EU as a nasal spray since 2019. It is administered only in a clinic for treatment-resistant depression and always in combination with an antidepressant.
LSD and ayahuasca
LSD is also being studied again, including for anxiety. Ayahuasca and its active ingredient, DMT, are being studied for depression and addiction. Those studies are even smaller and at an earlier stage. Read more about ayahuasca in our article about ayahuasca.
Psychedelic therapy isn't a pill you take and then feel better. It's an intensive process in which the guidance is just as important as the substance itself.
What's the situation like in the Netherlands?
In 2022, the government established the MDMA State Commission, led by Liesbeth van Ark. The commission issued its recommendation in July 2024. It recommended preparing for MDMA therapy for PTSD so that the Netherlands will be ready when the substance is approved. There is no treatment available yet. Psilocybin is also only available in the Netherlands within the context of scientific research.
Dutch universities and hospitals are also conducting research on psychedelics. Anyone who wants to participate in a study can only sign up through those institutions. Participants are carefully selected.
What does research say about safety?
In a clinical setting, serious problems are rarely observed. This is also because participants are rigorously screened. People with a personal or family history of psychosis or bipolar disorder are usually excluded from participation. Temporary side effects include headaches, nausea, anxiety, and elevated blood pressure. With MDMA, these are compounded by symptoms such as jaw clenching and an elevated body temperature.
- ✓Participants undergo medical and psychological evaluations in advance.
- ✓There are always two trained supervisors present.
- ✓The quantity and purity of the substance are precisely known.
- ✓The session is followed by follow-up care and integration.
Experimenting on your own is not therapy
Because of all the media attention, some people want to try it on their own. That’s understandable, but it’s not the same as therapy. At home, there’s no screening, no guidance, and no follow-up care. Furthermore, there can be interactions with medications, such as antidepressants and lithium. For someone with a mental health condition, a psychedelic experience can actually worsen symptoms.
Are you considering a psychedelic experience? If so, read about it first Preparing for a first trip and the role of a pet sitter. Are you taking any medications or undergoing treatment? If so, always discuss it with your doctor first.
What does the future hold?
In the coming years, results are expected from more large-scale studies on psilocybin. If those results are positive, an application for marketing authorization could be submitted to the European Medicines Agency (EMA). New studies are also underway for MDMA. At the same time, researchers point out unresolved questions. How long do the effects last? How can you accurately measure the drug’s effects if participants know whether they received the actual drug? And how can such intensive treatments be organized in an affordable way?
The research is therefore promising but not yet complete. Anyone who wants to follow these developments should do so through reliable sources such as universities and the Trimbos Institute.
How do psychedelics work in the brain?
Classic psychedelics such as psilocybin, LSD, and DMT primarily act through the serotonin 2A receptor. Psilocybin is converted into psilocin in the body. This substance binds to this receptor, temporarily altering the way different areas of the brain communicate with one another.
Researchers at Imperial College used brain scans to show that the so-called default mode network becomes less active during a trip. That network is involved in worrying and your self-image. Other areas of the brain, on the other hand, begin to communicate more with one another. According to a popular theory, this makes the brain temporarily more flexible, which could create the space needed to break out of entrenched thought patterns. That theory is interesting, but it hasn’t been proven yet.
MDMA works differently. It causes the brain to release large amounts of serotonin, dopamine, and norepinephrine. The hormone oxytocin is also released. Users often feel more connected and less anxious. In therapy, this could help people talk about traumatic memories without feeling overwhelmed. Read more about the role of serotonin in our blog post on serotonin and psychedelics.
Criticism and Open Questions
- ✓Blinding is difficult: participants usually notice whether they received the actual treatment.
- ✓Participants' expectations are often high, which can skew the results.
- ✓Many studies are small and follow people for only a short time.
- ✓It is difficult to distinguish the therapist's role from the effect of the medication.
- ✓Treatment involving two therapists per session is expensive and labor-intensive.
Scientists are therefore calling for more large-scale, independent studies with longer durations. Only then will it be possible to determine for whom a treatment is effective and how safe it is in the long term.
Microdosing and Therapy
In addition to high doses used in therapy, microdosing is also being studied. This involves taking a very small amount on a regular basis—so small that you don’t experience a “trip.” Many users are enthusiastic about it. Controlled studies, including those in which participants didn’t know whether they were receiving a placebo, have so far found little difference compared to a placebo. More research is needed in this area as well. Read more in our blog about Microdosing for beginners.
Important to know: Microdosing with magic truffles is legal in the Netherlands, but it is not a treatment. Smartific therefore makes no promises regarding its effects on your health.
Want to learn more? Then check out our articles on the San Pedro cactus en What is kambo?.
Learn more about psychedelics at Smartific
Magic truffles · Psychedelica · Microdosing truffles · Trip Stopper · Drug tests
Frequently Asked Questions About Psychedelic Therapy
Is psychedelic therapy legal in the Netherlands?
What did the MDMA State Commission recommend?
Where is MDMA therapy actually permitted?
Why did the FDA reject MDMA?
Can I participate in a study?
Important
This article is intended for informational purposes only. Smartific does not supply any products that violate Dutch law. If you have any doubts or need personal advice, always consult a doctor.
